Bayer's Myerstown, Penn. manufacturing facility is subject of a July 20 FDA warning letter citing failure to investigate out-of-specification findings in the production of Cipro Otic suspension. Bayer's response to FDA-483 issued after April inspection was "inadequate," agency maintains, and did not include "long-term assessment of the preservative effectiveness of benzyl alcohol" in the affected ciprofloxacin lots, the letter states
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth